VEGFA and ovarian carcinoma: It has been shown that treatment with adrenergic agonists could upregulate the production of matrix metalloproteinase (MMP)-2, MMP-9, and VEGF in ovarian cancer cell lines resulting in increased invasive capability[2,4].